ArticleScientific reports2023

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.

Andréa Witz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.